ADMA Biologics Inc $ADMA Shares Bought by B Group Inc.

Core Insights - B Group Inc. increased its stake in ADMA Biologics by 4.1% in Q3, owning 2,412,542 shares, which constitutes 26.9% of its holdings, valued at approximately $35.37 million [2] - Several institutional investors have also increased their positions in ADMA Biologics, with Marathon Capital Management raising its stake by 64.5% and Comerica Bank by 821.9% during the same period [3] - ADMA Biologics reported a revenue of $139.16 million for the last quarter, reflecting an 18.4% year-over-year increase, with an EPS of $0.20, matching analysts' expectations [5] Institutional Holdings - Institutional investors own 75.68% of ADMA Biologics' stock, indicating strong institutional interest [3] - Notable increases in holdings include Marathon Capital Management (64.5% increase) and Comerica Bank (821.9% increase) [3] Price Performance - ADMA Biologics shares opened at $15.15, with a 12-month low of $13.76 and a high of $25.67 [4] - The company has a market capitalization of $3.61 billion and a price-to-earnings ratio of 25.25 [4] Analyst Ratings - Zacks Research upgraded ADMA Biologics from "hold" to "strong-buy," while Wall Street Zen upgraded it from "hold" to "buy" [6] - The consensus rating for ADMA Biologics is "Buy," with a target price of $32.00 [6] Insider Transactions - Director Steve Elms purchased 7,000 shares at an average cost of $15.67, increasing his position by 0.34% [7] - COO Kaitlin M. Kestenberg-Messina sold 10,096 shares at an average price of $15.63, decreasing her ownership by 2.12% [7] Company Overview - ADMA Biologics is a biopharmaceutical company focused on developing and commercializing specialty plasma-derived biologics for treating primary immunodeficiency and infectious diseases [8] - The company's product portfolio includes BIVIGAM, a human immunoglobulin intravenous therapy approved in the U.S. [9]